International angiology : a journal of the International Union of Angiology
-
Review Meta Analysis
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation. ⋯ All-cause mortality was not different for any agent or regimen. In the absence of head-to-head comparisons, this network meta-analysis suggests that apixaban and dabigatran 110 mg bid may offer the best benefit-risk balance for stroke prevention in non-valvular atrial fibrillation. Dabigatran 150 mg bid may be preferred for patients with a high risk for embolism.
-
Comparative Study
A single-centre experience of the treatment of ruptured abdominal aortic aneurysms: clinical and anatomic characteristics of open versus endovascular repair.
The treatment of ruptured abdominal aortic aneurysms is a constant challenge for vascular surgeons and can be achieved either by endovascular repair or by an open surgical technique. Endovascular repair presents a higher 30-day survival rate. The aim of this study was to compare the clinical and anatomical characteristics and the outcomes of these two treatment techniques. ⋯ When certain anatomical characteristics are present and the hemodynamic condition of the patient allows it, endovascular treatment appears to be associated with better survival rates, both 30-day and overall.
-
Comparative Study
Influence of preoperative medical assessment prior to elective endovascular aneurysm repair for abdominal aortic aneurysm.
The aim of this study was to compare preoperative patient evaluation by a vascular physician with a standardized workup protocol prior to elective endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA), in terms of differences in patient medication and mortality. ⋯ Preoperative assessment by a vascular physician resulted in lower costs and improvement of medication against atherosclerosis, uncontrolled hypertension and perioperative ischemic cardiac events, but mortality was unaffected.
-
Editorial Comment
New oral anticoagulant in atrial fibrillation: are they comparable?